Please ensure Javascript is enabled for purposes of website accessibility

Ask a Fool: What's Your Foolish Opinion on Organovo?

By Dave Williamson – Feb 10, 2014 at 9:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Organovo is up 75% over the past 12 months but has pulled back 15% since the start of 2014. Is this a buy, sell, or hold today?

In this video as part of The Motley Fool's "Ask a Fool" series, Fool health-care analyst David Williamson takes a question from a Fool reader, who writes, "What's your Foolish opinion on Organovo (ONVO -2.56%)? Buy, sell, or hold?"

David introduces investors to the company, which is working to develop the ability to use 3-D printing technology to create human livers, which would facilitate medical testing for liver toxicity without having to test on actual humans. David also warns that even though this is a potentially disruptive force, it's still so early in the development of its product that there's still a lot of risk for investors here, and he advises keeping this as no more than a tiny percentage of any investment portfolio.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Organovo Holdings Stock Quote
Organovo Holdings
ONVO
$1.52 (-2.56%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.